Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 18 hours ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
Stephen Padilla, 6 days ago
Overweight and obesity show an inverse relationship with acne in a dose-dependent manner in young adults, according to a recent study. This suggests that the metabolically active adipose tissue plays a protective role in acne.

Nonalcoholic fatty liver disease ups risk of death

13 Aug 2019

Nonalcoholic fatty liver disease (NAFLD) heightens the risk of all-cause death but not from cardiovascular diseases (CVD) or cancer, reports a recent meta-analysis.

Accessing the databases of PubMed and Embase, researchers retrieved 14 studies that investigated the effect of NAFLD on mortality risk. Reports that used NAFLD patients as the reference group or assessed mortality in patients undergoing bariatric surgery or liver transplantation were ineligible. The Newcastle-Ottawa scale was used to evaluate methodological quality.

A total of 24,188 deaths were reported in the cumulative sample of 498,259 participants. Pooled analysis revealed a significantly higher death risk in NAFLD patients (hazard ratio [HR], 1.34, 95 percent CI 1.17–1.54), though the evidence had substantial heterogeneity (p<0.01).

Subsequent subgroup analyses found that NAFLD was a significant mortality hazard in women (four studies; HR, 1.49, 1.15–1.93) but not in men (four studies, HR, 1.08, 0.83–1.41). In contrast, there were no meaningful effect modifications according to age, sex, NAFLD severity, the presence of fibrosis or cirrhosis, follow-up duration, comorbidities, and the method used to diagnose NAFLD.

The effect of NAFLD on death risk appeared to be robust, as excluding four studies with large sample sizes did not change the principal findings. NAFLD also exerted a similar effect on the likelihood of death from liver disease (HR, 2.53, 1.23–5.18).

On the other hand, NAFLD had no apparent effect on the risk of death from CVDs (HR, 1.13, 0.92–1.38) and cancer (HR, 1.05, 0.89–1.25).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 18 hours ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
Stephen Padilla, 6 days ago
Overweight and obesity show an inverse relationship with acne in a dose-dependent manner in young adults, according to a recent study. This suggests that the metabolically active adipose tissue plays a protective role in acne.